Skip to main content
OpenTrials
Completed

NCT Number: NCT07686939

Clinical Validation of Continuous Glucose Monitoring in Glycemic Management of Critically Ill Sepsis Patients

Poor glycemic control is common in critically ill patients with sepsis and is associated with increased morbidity and mortality; however, achieving safe and effective glucose management in the ICU remains challenging with conventional intermittent monitoring. Continuous glucose monitoring (CGM) offers real-time interstitial glucose readings and has the potential to improve detection of dysglycemic events, enhance adherence to glycemic protocols, and reduce nursing workload. This prospective, randomized controlled trial was designed to evaluate the accuracy, clinical effectiveness, and operational utility of a factory-calibrated CGM system (FreeStyle Libre II) compared with standard blood glucose monitoring (fingerstick, arterial, and venous measurements) in septic ICU patients. The primary outcomes include CGM accuracy against reference methods, protocol adherence rates, time efficiency, and the incidence of hypoglycemic and hyperglycemic events. The findings of this trial will help determine whether CGM can provide a reliable, clinically feasible, and time-saving alternative for glycemic management in this high-risk population, thereby supporting its integration into routine ICU practice and informing future larger-scale studies on long-term outcomes and cost-effectiveness.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Taizhou Municipal Hospital

Taizhou, Zhejiang, 318000, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Confirmed infection accompanied by an increase in Sequential Organ Failure Assessment (SOFA) score of ≥ 2 points.
  • Written informed consent provided by the patient or legally authorized representative.

Exclusion criteria

  • Discharge against medical advice or transfer to another facility before study completion, leading to incomplete data.
  • Non-cooperation with study procedures.
  • Contraindications to the application of the flash glucose monitoring sensor (e.g., severe skin disease at insertion site, known allergy to sensor components).

Treatment and study plan

Continuous Glucose Monitoring (CGM) with FreeStyle Libre II System

Device

Intervention Group (CGM Group):

Patients receive continuous glucose monitoring using the factory-calibrated FreeStyle Libre II system (Abbott Diabetes Care Ltd, UK). A sensor is inserted subcutaneously on the posterior aspect of the upper arm and measures interstitial glucose levels in real time. Glucose values and trend data are displayed on a reader device and are accessible to the clinical team remotely. In addition to CGM, all patients in this group also undergo standard conventional monitoring (fingertip capillary glucose, arterial blood gas, and venous blood glucose measurements) per routine ICU practice. Insulin therapy is initiated when blood glucose reaches ≥10 mmol/L.

Primary outcomes

  1. Accuracy of CGM (MARD < 15%, ISO compliance, and DTS error grid Zones A+B)

    Time frame: Throughout the 1-2 week ICU stay

Secondary outcomes

  1. Protocol Adherence Rate

    Time frame: Throughout the 1-2 week ICU stay

    Percentage of completed glucose measurements relative to the total prescribed tests per protocol.Unit of Measure: % (percentage)

  2. Target Glucose Achievement Rate

    Time frame: Throughout the 1- to 2-week ICU stay.

    Proportion of glucose readings falling within the target range of 7.8-10.0 mmol/L.Unit of Measure: % (percentage)

  3. Hypoglycemia Detection Rate

    Time frame: Throughout the 1- to 2-week ICU stay.

    Incidence of hypoglycemic events (glucose ≤ 3.9 mmol/L) detected, calculated as number of events divided by total number of measurements × 100%.Unit of Measure: % (percentage)

  4. Hyperglycemia Detection Rate

    Time frame: hroughout the 1- to 2-week ICU stay.

    Incidence of hyperglycemic events (glucose ≥ 11.1 mmol/L) detected, calculated as number of events divided by total number of measurements × 100%.Unit of Measure: % (percentage)

  5. Nursing Time per Measurement

    Time frame: Throughout the 1- to 2-week ICU stay.

    Average time required for nursing staff to complete a single glucose measurement (from preparation to recording result).seconds (or minutes, as appropriate; your study reports seconds)

Sponsors and collaborators

Lead sponsor

Taizhou Hospital

Other

Registry information

Official study title

Clinical Validation of Continuous Glucose Monitoring in Glycemic Management of Critically Ill Sepsis Patients: A Prospective Randomized Clinical Study

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jul 7, 2026
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.